EA201591803A1 - Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев - Google Patents

Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев

Info

Publication number
EA201591803A1
EA201591803A1 EA201591803A EA201591803A EA201591803A1 EA 201591803 A1 EA201591803 A1 EA 201591803A1 EA 201591803 A EA201591803 A EA 201591803A EA 201591803 A EA201591803 A EA 201591803A EA 201591803 A1 EA201591803 A1 EA 201591803A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mva
infants
immune response
protective immune
newborns
Prior art date
Application number
EA201591803A
Other languages
English (en)
Other versions
EA034825B1 (ru
Inventor
Седрик Кеминай
Ариане Фолькманн
Пол Чаплин
Марк Сутер
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA201591803A1 publication Critical patent/EA201591803A1/ru
Publication of EA034825B1 publication Critical patent/EA034825B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к композициям и способам индукции защитного иммунного ответа против поксвируса у новорожденных людей или младенцев-людей в возрасте менее 6 месяцев. Настоящее изобретение включает введение разовой высокой дозы MVA новорожденному человеку или младенцу-человеку в возрасте менее 6 месяцев, причем введение индуцирует защитные Т- и В-клеточные ответы против поксвируса у новорожденного человека или младенца-человека.
EA201591803A 2013-03-15 2014-03-14 Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев EA034825B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788722P 2013-03-15 2013-03-15
PCT/EP2014/000693 WO2014139687A1 (en) 2013-03-15 2014-03-14 Single high dose of mva induces a protective immune response in neonates and infants

Publications (2)

Publication Number Publication Date
EA201591803A1 true EA201591803A1 (ru) 2016-02-29
EA034825B1 EA034825B1 (ru) 2020-03-25

Family

ID=50389388

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591803A EA034825B1 (ru) 2013-03-15 2014-03-14 Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев

Country Status (17)

Country Link
US (1) US9707291B2 (ru)
EP (2) EP3708187A1 (ru)
JP (1) JP6480875B2 (ru)
KR (1) KR102269491B1 (ru)
CN (1) CN105101993A (ru)
AU (4) AU2014231229A1 (ru)
BR (1) BR112015021781A2 (ru)
CA (1) CA2905569C (ru)
EA (1) EA034825B1 (ru)
HK (1) HK1216860A1 (ru)
IL (1) IL241059B (ru)
MX (1) MX2015011388A (ru)
MY (1) MY175269A (ru)
SG (2) SG10201707340XA (ru)
UA (1) UA126785C2 (ru)
WO (1) WO2014139687A1 (ru)
ZA (1) ZA201507017B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905569C (en) * 2013-03-15 2023-07-25 Bavarian Nordic A/S Single high dose of modified vaccinia virus ankara induces a protective immune response in neonates and infants
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117596D0 (en) * 1991-08-15 1991-10-02 John Gibson Lifting Gear Ltd Pulling system
US5471902A (en) * 1994-02-22 1995-12-05 Athenry Enterprises Limited Tuning system for pianos
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
EP1598425A1 (en) * 2000-11-23 2005-11-23 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
ES2288609T5 (es) * 2002-04-19 2017-11-13 Bavarian Nordic A/S Virus vaccinia ankara modificado para la vacunación de neonatos
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
NZ556409A (en) * 2005-02-23 2010-09-30 Bavarian Nordic As Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
US20100011451A1 (en) * 2006-09-08 2010-01-14 Paul Chaplin Phenotypic and genotypic differences of mva strains
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
CA2767924A1 (en) * 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
US9463238B2 (en) * 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
US10111946B2 (en) * 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
KR102435054B1 (ko) * 2012-08-01 2022-08-22 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
CA2905569C (en) * 2013-03-15 2023-07-25 Bavarian Nordic A/S Single high dose of modified vaccinia virus ankara induces a protective immune response in neonates and infants

Also Published As

Publication number Publication date
CA2905569C (en) 2023-07-25
US9707291B2 (en) 2017-07-18
US20160030551A1 (en) 2016-02-04
EA034825B1 (ru) 2020-03-25
EP2968524A1 (en) 2016-01-20
MY175269A (en) 2020-06-17
IL241059A0 (en) 2015-11-30
NZ711569A (en) 2021-03-26
JP6480875B2 (ja) 2019-03-13
JP2016514114A (ja) 2016-05-19
BR112015021781A2 (pt) 2017-07-18
HK1216860A1 (zh) 2016-12-09
AU2022235527A1 (en) 2022-10-13
IL241059B (en) 2020-10-29
EP3708187A1 (en) 2020-09-16
KR20150129027A (ko) 2015-11-18
AU2020260472A1 (en) 2020-11-26
AU2014231229A1 (en) 2015-09-17
AU2019200977A1 (en) 2019-02-28
ZA201507017B (en) 2018-12-19
CA2905569A1 (en) 2014-09-18
CN105101993A (zh) 2015-11-25
SG11201507192SA (en) 2015-10-29
AU2022235527B2 (en) 2023-10-26
SG10201707340XA (en) 2017-10-30
KR102269491B1 (ko) 2021-06-25
UA126785C2 (uk) 2023-02-08
MX2015011388A (es) 2016-02-03
WO2014139687A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
BR112015027281A2 (pt) combinações de dosagens para reduzir respostas imunológicas humorais indesejadas
MY169326A (en) Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
BR112017001796A2 (pt) composições de flagelina e seus usos
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
BR112013000596A2 (pt) piridinas e tiazinas fusionadas e seus usos.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
MX2014000895A (es) Galacto-oligosacaridos para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
PH12016501114B1 (en) Newly identified peptides for use in the induction of oral tolerance in young mammals
PH12019502501A1 (en) Preterm infant formula containing butyrate and uses thereof
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
EA201591803A1 (ru) Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina
CU20100083A7 (es) Tolerogenos adyuvados como vacuna de malaria
TR201714726A1 (tr) Antikolinerjik bir etken madde içeren farmasötik formülasyon.
Thanik Influenza virus vaccine
CN302388765S (zh) 椅子

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM